PI3K通路在肿瘤免疫微环境中的作用机制

摘要/Abstract

摘要：

免疫抑制性肿瘤微环境是影响免疫检查点抑制剂疗效的重要因素之一。磷脂酰肌醇3-激酶（PI3K）相关信号通路是参与肿瘤发生发展的重要通路，该通路的异常激活与肿瘤免疫抑制性微环境的形成有着错综复杂的联系。深入讨论PI3K相关通路在肿瘤微环境中的作用机制，可以为提高免疫治疗疗效提供一定的方向和思路，发掘免疫治疗的潜力。

关键词:肿瘤,PI3K通路,肿瘤微环境,免疫治疗

Abstract:

Immunosuppressive tumor microenvironment is one of the important factors affecting the efficacy of immune checkpoint inhibitors. The phosphatidylinositol 3-kinase （PI3K）-related signaling pathway is an important pathway involved in the occurrence and development of tumors， and the abnormal activation of this pathway is inextricably linked with the immunosuppressive tumor microenvironment. In-depth discussion of the mechanism of PI3K-related pathways in the tumor microenvironment can provide certain directions and ideas for improving the efficacy of immunotherapy， and explore the potential of immunotherapy.

Key words:Neoplasms,PI3K pathway,Tumor microenvironment,Immunotherapy

李瑛珏, 路丹. PI3K通路在肿瘤免疫微环境中的作用机制[J]. 国际肿瘤学杂志, 2022, 49(11): 677-680.

Li Yingjue, Lu Dan. Mechanism of PI3K pathway in tumor immune microenvironment[J]. Journal of International Oncology, 2022, 49(11): 677-680.

参考文献37

[1]	Roma-Rodrigues C, Mendes R, Baptista PV, et al. Targeting tumor microenvironment for cancer therapy[J]. Int J Mol Sci, 2019, 20(4): 840. DOI: 10.3390/ijms20040840. doi:10.3390/ijms20040840
[2]	O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy[J]. Nat Rev Clin Oncol, 2019, 16(3): 151-167. DOI: 10.1038/s41571-018-0142-8. doi:10.1038/s41571-018-0142-8pmid:30523282
[3]	Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med, 2012, 366(26): 2443-2454. DOI: 10.1056/NEJMoa1200690. doi:10.1056/NEJMoa1200690
[4]	Wu X, Gu Z, Chen Y, et al. Application of PD-1 blockade in cancer immunotherapy[J]. Comput Struct Biotechnol J, 2019, 17: 661-674. DOI: 10.1016/j.csbj.2019.03.006. doi:10.1016/j.csbj.2019.03.006
[5]	Zappasodi R, Merghoub T, Wolchok JD. Emerging concepts for immune checkpoint blockade-based combination therapies[J]. Cancer Cell, 2018, 33(4): 581-598. DOI: 10.1016/j.ccell.2018.03.005. doi:S1535-6108(18)30109-0pmid:29634946
[6]	Ramapriyan R, Caetano MS, Barsoumian HB, et al. Altered cancer metabolism in mechanisms of immunotherapy resistance[J]. Pharmacol Ther, 2019, 195: 162-171. DOI: 10.1016/j.pharmthera.2018.11.004. doi:10.1016/j.pharmthera.2018.11.004
[7]	du Rusquec P, Blonz C, Frenel JS, et al. Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer[J]. Ther Adv Med Oncol, 2020, 12: 1758835920940939. DOI: 10.1177/1758835920940939. doi:10.1177/1758835920940939
[8]	Vanhaesebroeck B, Perry MWD, Brown JR, et al. PI3K inhibitors are finally coming of age[J]. Nat Rev Drug Discov, 2021, 20(10): 741-769. DOI: 10.1038/s41573-021-00209-1. doi:10.1038/s41573-021-00209-1pmid:34127844
[9]	Fruman DA, Chiu H, Hopkins BD, et al. The PI3K pathway in human disease[J]. Cell, 2017, 170(4): 605-635. DOI: 10.1016/j.cell.2017.07.029. doi:S0092-8674(17)30865-6pmid:28802037
[10]	Hanahan D. Hallmarks of cancer: new dimensions[J]. Cancer Discov, 2022, 12(1): 31-46. DOI: 10.1158/2159-8290.CD-21-1059. doi:10.1158/2159-8290.CD-21-1059pmid:35022204
[11]	Liu M, Wei F, Wang J, et al. Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1^-PD-L1⁺Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer[J]. Cell Death Dis, 2021, 12(5): 465. DOI: 10.1038/s41419-021-03745-1. doi:10.1038/s41419-021-03745-1
[12]	Farhood B, Najafi M, Mortezaee K. CD8⁺cytotoxic T lymphocytes in cancer immunotherapy: a review[J]. J Cell Physiol, 2019, 234(6): 8509-8521. DOI: 10.1002/jcp.27782. doi:10.1002/jcp.27782pmid:30520029
[13]	Xiang X, Wang J, Lu D, et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy[J]. Signal Transduct Target Ther, 2021, 6(1): 75. DOI: 10.1038/s41392-021-00484-9. doi:10.1038/s41392-021-00484-9
[14]	Kaneda MM, Messer KS, Ralainirina N, et al. PI3Kγ is a molecular switch that controls immune suppression[J]. Nature, 2016, 539(7629): 437-442. DOI: 10.1038/nature19834. doi:10.1038/nature19834
[15]	Kaneda MM, Cappello P, Nguyen AV, et al. Macrophage PI3Kγ drives pancreatic ductal adenocarcinoma progression[J]. Cancer Discov, 2016, 6(8): 870-885. DOI: 10.1158/2159-8290.CD-15-1346. doi:10.1158/2159-8290.CD-15-1346pmid:27179037
[16]	Yang C, Chen C, Xiao Q, et al. Relationship between PTEN and angiogenesis of esophageal squamous cell carcinoma and the underlying mechanism[J]. Front Oncol, 2021, 11: 739297. DOI: 10.3389/fonc.2021.739297. doi:10.3389/fonc.2021.739297
[17]	Shen M, Wang J, Yu W, et al. A novel MDSC-induced PD-1^-PD-L1⁺B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties[J]. Oncoimmunology, 2018, 7(4): e1413520. DOI: 10.1080/2162402X.2017.1413520. doi:10.1080/2162402X.2017.1413520
[18]	Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity[J]. Nat Rev Immunol, 2021, 21(8): 485-498. DOI: 10.1038/s41577-020-00490-y. doi:10.1038/s41577-020-00490-ypmid:33526920
[19]	Motz GT, Santoro SP, Wang LP, et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors[J]. Nat Med, 2014, 20(6): 607-615. DOI: 10.1038/nm.3541. doi:10.1038/nm.3541pmid:24793239
[20]	Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment[J]. Science, 2015, 348(6230): 74-80. DOI: 10.1126/science.aaa6204. doi:10.1126/science.aaa6204pmid:25838376
[21]	Chang CZ, Wu SC, Chang CM, et al. Arctigenin, a potent ingre-dient of Arctium lappa L., induces endothelial nitric oxide synthase and attenuates subarachnoid hemorrhage-induced vasospasm through PI3K/Akt pathway in a rat model[J]. Biomed Res Int, 2015, 2015: 490209. DOI: 10.1155/2015/490209. doi:10.1155/2015/490209
[22]	Shen W, Li HL, Liu L, et al. Expression levels of PTEN, HIF-1α, and VEGF as prognostic factors in ovarian cancer[J]. Eur Rev Med Pharmacol Sci, 2017, 21(11): 2596-2603.
[23]	Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy[J]. Cancer Discov, 2016, 6(2): 202-216. DOI: 10.1158/2159-8290.CD-15-0283. doi:10.1158/2159-8290.CD-15-0283pmid:26645196
[24]	Lastwika KJ, Wilson W 3rd, Li QK, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer[J]. Cancer Res, 2016, 76(2): 227-238. DOI: 10.1158/0008-5472.CAN-14-3362. doi:10.1158/0008-5472.CAN-14-3362pmid:26637667
[25]	Gao Y, Yang J, Cai Y, et al. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling[J]. Int J Cancer, 2018, 143(4): 931-943. DOI: 10.1002/ijc.31357. doi:10.1002/ijc.31357pmid:29516506
[26]	Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint[J]. Immunity, 2018, 48(3): 434-452. DOI: 10.1016/j.immuni.2018.03.014. doi:S1074-7613(18)30090-6pmid:29562194
[27]	Yao X, Tu Y, Xu Y, et al. Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages[J]. J Cell Mol Med, 2020, 24(17): 9560-9573. DOI: 10.1111/jcmm.15367. doi:10.1111/jcmm.15367
[28]	Mansour FA, Al-Mazrou A, Al-Mohanna F, et al. PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis[J]. Oncoimmunology, 2020, 9(1): 1729299. DOI: 10.1080/2162402X.2020.1729299. doi:10.1080/2162402X.2020.1729299
[29]	Li X, Wenes M, Romero P, et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy[J]. Nat Rev Clin Oncol, 2019, 16(7): 425-441. DOI: 10.1038/s41571-019-0203-7. doi:10.1038/s41571-019-0203-7pmid:30914826
[30]	Scharping NE, Menk AV, Moreci RS, et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction[J]. Immunity, 2016, 45(3): 701-703. DOI: 10.1016/j.immuni.2016.08.009. doi:S1074-7613(16)30333-8pmid:27653602
[31]	Lim S, Liu H, Madeira da Silva L, et al. Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1α[J]. Cancer Res, 2016, 76(8): 2231-2242. DOI: 10.1158/0008-5472.CAN-15-1538. doi:10.1158/0008-5472.CAN-15-1538pmid:27197253
[32]	Katheder NS, Khezri R, O'Farrell F, et al. Microenvironmental autophagy promotes tumour growth[J]. Nature, 2017, 541(7637): 417-420. DOI: 10.1038/nature20815. doi:10.1038/nature20815
[33]	Verhoeven J, Baelen J, Agrawal M, et al. Endothelial cell autophagy in homeostasis and cancer[J]. FEBS Lett, 2021, 595(11): 1497-1511. DOI: 10.1002/1873-3468.14087. doi:10.1002/1873-3468.14087pmid:33837545
[34]	Janku F, McConkey DJ, Hong DS, et al. Autophagy as a target for anticancer therapy[J]. Nat Rev Clin Oncol, 2011, 8(9): 528-539. DOI: 10.1038/nrclinonc.2011.71. doi:10.1038/nrclinonc.2011.71pmid:21587219
[35]	Xu Z, Han X, Ou D, et al. Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy[J]. Appl Microbiol Biotechnol, 2020, 104(2): 575-587. DOI: 10.1007/s00253-019-10257-8. doi:10.1007/s00253-019-10257-8pmid:31832711
[36]	Yamamoto K, Venida A, Yano J, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-Ⅰ[J]. Nature, 2020, 581(7806): 100-105. DOI: 10.1038/s41586-020-2229-5. doi:10.1038/s41586-020-2229-5
[37]	Jabbarzadeh Kaboli P, Salimian F, Aghapour S, et al. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer—a comprehensive review from chemotherapy to immunotherapy[J]. Pharmacol Res, 2020, 156: 104806. DOI: 10.1016/j.phrs.2020.104806. doi:10.1016/j.phrs.2020.104806